Nuopu Regenerative Medicine
Develops and manufactures patient-specific, biodegradable bone regeneration scaffolds for oral and maxillofacial surgery using its proprietary OPUS bio-3D printing extrusion platform.
- CEO / Founder
- Xi Yang
- Team Size
- 11-50
- Stage
- Established
- Total Funding
- $Tens of millions
- Latest Round
- Series A
- Key Investors
- YuanSheng Capital; Wuzhong Hi-Tech Venture Capital
Technology & Products
Key Products
OPUS bio-3D printing platform; NMPA-certified Class III medical device bone filler for alveolar defect repair
Technological Advantage
Proprietary extrusion-based bioprinting process for creating single-piece, biodegradable, porous scaffolds with controlled architecture, protected by patents (e.g., CN105802851A, CN119283364A). The regulatory approval creates a significant barrier to entry in the Chinese medical AM market.
Differentiation
Value Proposition
Eliminates secondary trauma from autologous bone harvesting and immunological risks of allografts by providing a personalized, structurally supportive, and osteoconductive scaffold that improves anatomical fit and clinical outcomes in complex bone defects.
How They Differentiate
Focuses on regulatory-approved, patient-specific bone scaffolds via extrusion bioprinting, unlike generic bone graft substitutes or non-resorbable implants.
Market & Competition
Target Customers
Hospitals, dental clinics, and surgeons specializing in oral and maxillofacial reconstruction
Industry Verticals
Medical Devices; Regenerative Medicine; Dentistry
Competitors
Aspect Biosystems; CELLINK; Allevi
Growth & Milestones
Growth Metrics
Received China's first Class III medical device registration for an additively manufactured oral bone filler material in April 2026.
Major Milestones
Obtained NMPA Class III medical device registration certificate for its AM bone filler (first in China for this technology)